AMA Corporation Plc AI Stock Analysis
Want to see FR:ALAMA full AI Analyst Report?
AMA Corporation Plc (ALAMA) AI Stock Analysis
AMA Corporation Plc
(Paris:ALAMA)
The overall score is low because the company’s financial profile is deeply loss-making with declining revenues, negative equity, and sustained cash burn, leaving little buffer to absorb further setbacks. Technical indicators reinforce this cautious view, showing a clear downtrend with the price below all major moving averages despite an oversold reading that only hints at a potential short-term bounce. Valuation adds limited support, as a negative P/E and lack of dividend mean the stock currently has no earnings or income foundation, keeping the investment thesis high risk and dependent on future operational turnaround.
AMA Corporation Plc (ALAMA) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 6.02M
- Dividend Yield
- ―
- Average Volume (3M)
- 21.84K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.17
- Revenue Growth
- -20.28%
- EPS Growth
- 22.97%
- Country
- France
- Employees
- 27
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
AMA Corporation Plc Business Overview & Revenue Model
Company Description
AMA Corporation Ltd delivers remote support solutions to industrial organizations, service providers, and medical institutions across the globe. The company develops its XpertEye assisted reality platform, which facilitates applications like remote g...
How the Company Makes Money
null
AMA Corporation Plc Financial Statement Overview
Summary
Financial performance is very weak: revenues have declined for several years, losses are large and persistent, equity turned negative in 2025, and cash flows remain consistently negative, although loss and cash burn reduction since 2022 provide a modest positive offset.
Income Statement
24NegativeBalance Sheet
18Very NegativeCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.99M | 1.99M | 2.49M | 3.01M | 4.28M | 6.57M |
| Gross Profit | 1.42M | 1.42M | 1.97M | -688.00K | 4.90M | 8.04M |
| EBITDA | -4.99M | -4.99M | -6.36M | -6.87M | -10.27M | -6.52M |
| Net Income | -5.67M | -5.67M | -7.34M | -8.04M | -21.39M | -9.84M |
Balance Sheet | ||||||
| Total Assets | 4.43M | 4.43M | 9.17M | 12.75M | 13.65M | 38.22M |
| Cash, Cash Equivalents and Short-Term Investments | 2.09M | 2.09M | 5.82M | 9.39M | 8.60M | 20.64M |
| Total Debt | 2.79M | 2.79M | 4.03M | 3.96M | 4.53M | 4.70M |
| Total Liabilities | 5.37M | 5.37M | 6.62M | 6.97M | 7.85M | 11.32M |
| Stockholders Equity | -991.00K | -991.00K | 2.50M | 5.71M | 5.68M | 27.29M |
Cash Flow | ||||||
| Free Cash Flow | -4.84M | -4.84M | -6.39M | -5.79M | -13.00M | -10.28M |
| Operating Cash Flow | -4.80M | -4.80M | -6.28M | -5.74M | -10.52M | -5.10M |
| Investing Cash Flow | 37.00K | 37.00K | 114.00K | 149.00K | -1.24M | -5.22M |
| Financing Cash Flow | 1.06M | 1.06M | 2.59M | 6.46M | -293.00K | 29.67M |
AMA Corporation Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALAMA, the sentiment is Neutral. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.13, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 59.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALAMA.
AMA Corporation Plc Peers Comparison
Overall Rating
FR:ALERS58Neutral
FR:ALIKO46Neutral
FR:ALMDT43Neutral
FR:ALAMA40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | EUR 259.38M | 37.71 | 3.89% | ― | 6.28% | 204.56% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | EUR 22.89M | -5.31 | -22.49% | ― | 37.28% | 7.83% | |
| 43Neutral | EUR 213.68M | -3.54 | 271.64% | ― | 2.16% | -5.26% | |
| 40Underperform | EUR 6.02M | -0.75 | ― | ― | -20.28% | 22.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALAMA | AMA Corporation Plc | 0.11 | -0.07 | -37.78% | |
| FR:ALERS | Eurobio-Scientific SA | 26.40 | 1.55 | 6.24% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.90 | -0.38 | -29.69% | |
| FR:ALIKO | Ikonisys SA | 1.45 | -0.01 | -0.68% | |
| FR:ALMDT | Median Technologies | 4.36 | 1.40 | 47.30% | |
| FR:ALBIO | Biosynex SA | 0.82 | 0.31 | 60.78% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026
